enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 216,700 shares, a growth of 38.7% from the August 31st total of 156,200 shares. Based on an average daily trading volume, of 123,800 shares, the days-to-cover ratio is presently 1.8 days. Currently, 1.3% of the shares of the stock are sold short.
enGene Stock Up 10.0 %
Shares of NASDAQ ENGN traded up $0.55 during trading on Friday, hitting $6.05. The stock had a trading volume of 432,716 shares, compared to its average volume of 99,694. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The company has a market capitalization of $267.20 million, a PE ratio of -3.52 and a beta of -0.68. The firm has a fifty day moving average of $7.00 and a two-hundred day moving average of $10.78. enGene has a 12 month low of $4.42 and a 12 month high of $43.00.
enGene (NASDAQ:ENGN – Get Free Report) last issued its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, equities research analysts forecast that enGene will post -1.64 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on ENGN shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and set a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $33.67.
Read Our Latest Stock Report on ENGN
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- Stock Analyst Ratings and Canadian Analyst Ratings
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- ETF Screener: Uses and Step-by-Step Guide
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is a SEC Filing?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.